Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized immunosuppression with donor modified immune cells (MIC) vs standard-of-care in living donor kidney transplantation
2021-000561-33Phase 2Active
- Sponsor
- TolerogenixX
- Start
- Jul 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Kidney allograft status (RTx), kidney transplant and end-stage kidney disease (ESKD) comparing MIC individualized immunosuppression with Standard-of-care immunosuppression (2 arms). Primary endpoint: Operational tolerance-like phenotype at Day 367. Started Jul 2021; status: active.
02
Drugs
MIC-Tx
03
Conditions
Kidney allograft status (RTx)kidney transplantend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2021-000561-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000561-33.